Your browser doesn't support javascript.
loading
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell, Johannes; Maddocks, Kami J; González-Barca, Eva; Jurczak, Wojciech; Liberati, Anna Marina; De Vos, Sven; Nagy, Zsolt; Obr, Ales; Gaidano, Gianluca; Abrisqueta, Pau; Kalakonda, Nagesh; André, Marc; Dreyling, Martin; Menne, Tobias; Tournilhac, Olivier; Augustin, Marinela; Rosenwald, Andreas; Dirnberger-Hertweck, Maren; Weirather, Johannes; Ambarkhane, Sumeet; Salles, Gilles.
Afiliação
  • Duell J; Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany.
  • Maddocks KJ; Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • González-Barca E; Department of Hematology, Institut Catalá d'Oncologia (ICO), Hospital Duran i Reynals, Universitat de Barcelona, Barcelona, Spain.
  • Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland.
  • Liberati AM; Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy.
  • De Vos S; Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, CA, USA.
  • Nagy Z; 1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
  • Obr A; Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic.
  • Gaidano G; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
  • Abrisqueta P; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Kalakonda N; Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, United Kingdom.
  • André M; Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
  • Dreyling M; Department of Medicine III, LMU University Hospital, Munich, Germany.
  • Menne T; Department of Haematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.
  • Tournilhac O; Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, Clermont-Ferrand, France.
  • Augustin M; Department of Hematology and Oncology, Paracelcus Medical University, Klinikum Nürnberg, Nürnberg, Germany.
  • Rosenwald A; Institute of Pathology, University of Würzburg, Würzburg, Germany.
  • Dirnberger-Hertweck M; MorphoSys AG, Planegg, Germany.
  • Weirather J; MorphoSys AG, Planegg, Germany.
  • Ambarkhane S; MorphoSys AG, Planegg, Germany.
  • Salles G; Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon, France. sallesg@mskcc.org.
Haematologica ; 106(9): 2417-2426, 2021 09 01.
Article em En | MEDLINE | ID: mdl-34196165
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha